$597.9 M

INSY Mkt cap, 14-Jun-2018

$23.9 M

Insys Therapeutics Revenue Q1, 2018
Insys Therapeutics Gross profit (Q1, 2018)21.7 M
Insys Therapeutics Gross profit margin (Q1, 2018), %90.8%
Insys Therapeutics Net income (Q1, 2018)-20.4 M
Insys Therapeutics EBIT (Q1, 2018)-20.2 M
Insys Therapeutics Cash, 31-Mar-201818.5 M

Insys Therapeutics Financials

Insys Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

99.3 m222.1 m330.8 m242.3 m140.7 m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7 m28.9 m25.4 m20.6 m

Gross profit

86.6 m301.9 m216.9 m120.1 m

Gross profit Margin, %

87%91%90%85%

Sales and marketing expense

69.7 m48.9 m

R&D expense

73.9 m63 m

General and administrative expense

62.1 m67.6 m

Operating expense total

205.7 m339.1 m

EBIT

32.6 m64 m92.4 m7.3 m(219 m)

EBIT margin, %

33%29%28%3%(156%)

Interest expense

928 k

Interest income

502 k1 m1.9 m

Pre tax profit

31.6 m93 m8.4 m(217.2 m)

Income tax expense

8.8 m10.8 m

Net Income

40.4 m38 m58.5 m7.6 m(228 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

29.2 m41.6 m55.7 m58.3 m70.8 m77.6 m91.3 m62 m67.1 m55.2 m36 m42.6 m30.7 m23.9 m

Cost of goods sold

3.1 m4.8 m6.6 m5.4 m6.4 m8.3 m7.7 m4.6 m6.3 m4.7 m4.6 m3.9 m7.5 m2.2 m

Gross profit

26.1 m36.9 m49.1 m52.9 m64.4 m69.3 m83.6 m57.3 m60.8 m50.5 m31.3 m38.7 m23.2 m21.7 m

Gross profit Margin, %

89%89%88%91%91%89%92%93%91%92%87%91%76%91%

Sales and marketing expense

8 m11.6 m14.1 m15.1 m20.9 m22 m19.2 m19.8 m19.7 m16.7 m15.7 m13.3 m12.8 m9.1 m

R&D expense

1.7 m4 m9.2 m7 m10.6 m17.8 m12.3 m20.5 m22.9 m16.5 m12.9 m14.1 m19.6 m12.3 m

General and administrative expense

4.3 m8.6 m10.7 m10.8 m21.2 m15.3 m13.7 m14.7 m13.9 m17.7 m15 m17.1 m15.7 m19.9 m

Operating expense total

14 m24.2 m34 m32.9 m52.8 m57.4 m44.4 m55 m56.5 m50.8 m43.6 m49 m198.9 m41.9 m

EBIT

12.1 m12.7 m15.2 m20 m11.6 m12 m39.1 m2.3 m4.3 m(328 k)(12.3 m)(10.3 m)(175.7 m)(20.2 m)

EBIT margin, %

42%30%27%34%16%15%43%4%6%(1%)(34%)(24%)(573%)(85%)

Interest expense

8 k

Interest income

8 k6 k26 k43 k125 k105 k128 k225 k256 k281 k435 k465 k510 k503 k

Pre tax profit

12.1 m12.7 m15.2 m20.1 m11.8 m12.1 m39.2 m2.6 m4.6 m(47 k)(11.9 m)(9.8 m)(175.3 m)(20.2 m)

Income tax expense

532 k5 m5.7 m8.6 m3.7 m4.8 m13.1 m131 k240 k(237 k)(5.3 m)(1.7 m)(9 m)171 k

Net Income

7.7 m9.5 m11.5 m8 m7.3 m26.1 m2.4 m4.4 m190 k(6.5 m)(8.2 m)(166.3 m)(20.4 m)

Insys Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.4 m58.1 m79.5 m104.6 m32 m

Accounts Receivable

Inventories

14.5 m34.8 m41.7 m21.7 m17.4 m

Current Assets

82.2 m151 m253.2 m231 m175.9 m

PP&E

10.1 m38.4 m43.2 m55.2 m

Total Assets

100.6 m215.1 m351.2 m356.1 m279.1 m

Accounts Payable

16.6 m27.5 m36.4 m27.4 m30.4 m

Short-term debt

Current Liabilities

21.1 m45.7 m88.9 m78.6 m207.2 m

Long-term debt

Total Liabilities

86.5 m215.8 m

Common Stock

354 k719 k719 k736 k

Preferred Stock

Additional Paid-in Capital

168.5 m216.4 m245.7 m256.5 m278.4 m

Retained Earnings

(89 m)(51.1 m)7.4 m12.7 m(215.4 m)

Total Equity

79.5 m165.7 m253.7 m269.6 m63.3 m

Financial Leverage

1.3 x1.3 x1.4 x1.3 x4.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

31.3 m40 m46.1 m47.4 m70.1 m74 m94 m73.8 m69.3 m93.5 m68.4 m49.8 m35.8 m18.5 m

Accounts Receivable

12.4 m19.1 m

Inventories

11.7 m19.4 m24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m21.3 m20 m18.4 m16.3 m

Current Assets

57.7 m91.3 m102.2 m128.7 m182.1 m198.2 m236.6 m220.8 m234 m235.2 m196.9 m197.2 m179.9 m166.7 m

PP&E

8.3 m12.6 m17.4 m24.1 m33.8 m35.5 m36.7 m39.6 m39.9 m41.3 m46 m49.1 m53.9 m54.8 m

Total Assets

66 m122.2 m149.9 m188.2 m247.2 m275 m314.1 m325 m338 m353.1 m337.6 m337.6 m323.1 m253.9 m

Accounts Payable

12.2 m16.7 m15.1 m24.5 m36.6 m30.6 m24.2 m25.7 m22.2 m17.5 m28.2 m23 m31.2 m29.4 m

Current Liabilities

18.5 m24.9 m28.3 m43.2 m58.8 m67.3 m69.6 m67.5 m71.3 m76.6 m61.9 m63.1 m208.9 m197.8 m

Total Liabilities

18.5 m24.9 m28.3 m43.2 m62.6 m71.1 m77.5 m75 m78.8 m84.3 m69.8 m71.2 m217.1 m206.6 m

Common Stock

5 k345 k348 k357 k718 k720 k715 k716 k718 k721 k727 k731 k738 k

Preferred Stock

Additional Paid-in Capital

160.7 m178.7 m193.1 m205.1 m227.3 m239 m245.5 m239.4 m244.3 m253.8 m261.2 m268 m273.9 m282 m

Retained Earnings

(113.1 m)(81.4 m)(71.9 m)(60.4 m)(43 m)(35.7 m)(9.6 m)9.9 m14.2 m14.4 m6.1 m(2 m)(168.4 m)(234.9 m)

Total Equity

97.3 m121.5 m145 m184.6 m204 m236.6 m250 m259.3 m268.8 m267.8 m266.4 m106 m47.4 m

Financial Leverage

1.3 x1.2 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x3 x5.4 x

Insys Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

40.4 m58.5 m7.6 m(228 m)

Depreciation and Amortization

1.8 m2.5 m5.3 m6.2 m7.3 m

Accounts Receivable

(13 m)(10 m)(22 m)26.6 m(859 k)

Inventories

(7.4 m)(20 m)(6.9 m)15 m2.3 m

Accounts Payable

Cash From Operating Activities

24.2 m49.7 m100.9 m58.9 m(60.7 m)

Purchases of PP&E

(5.1 m)(22.2 m)(13.8 m)(10.6 m)(16.7 m)

Cash From Investing Activities

(5.5 m)(69.9 m)(88.7 m)(22 m)(17.8 m)

Cash From Financing Activities

26.3 m32.9 m9.3 m(11.7 m)5.8 m

Income Taxes Paid

991 k3 m15.4 m10.7 m2.1 m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

7.7 m9.5 m11.5 m8 m7.3 m26.1 m2.4 m4.4 m190 k(6.5 m)(20.4 m)

Depreciation and Amortization

1.9 m

Accounts Receivable

6 m

Inventories

24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m1 m

Accounts Payable

15.1 m24.5 m36.6 m30.6 m24.2 m25.7 m22.2 m17.5 m28.2 m

Cash From Operating Activities

(17.4 m)

Purchases of PP&E

(760 k)

Cash From Investing Activities

3.4 m

Cash From Financing Activities

524 k

Income Taxes Paid

43 k

Insys Therapeutics Ratios

USDY, 2018

Financial Leverage

5.4 x
Report incorrect company information